Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study

By Hill Simon   Elhilali Mostafa   Millard Richard J   Dwyer Peter L   Lheritier Karine   Kawakami Fernando T.   Steel Michael  

Current Medical Research and Opinion, Vol. 23, Iss. 11, 2007-11 ,pp. : 2697-2704

Informa Healthcare

Access to resources Recommend Favorite

Darifenacin treatment of patients ≥ 65 years with overactive bladder: results of a randomized, controlled, 12-week trial

By Chapple C   DuBeau C   Ebinger U   Rekeda L   Viegas A  

Current Medical Research and Opinion, Vol. 23, Iss. 10, 2007-10 ,pp. : 2347-2358

Informa Healthcare

Access to resources Recommend Favorite

Patient experience and satisfaction with Onabotulinumtoxin A for refractory overactive bladder

By  

BJU INTERNATIONAL, Vol. 116, Iss. 3, 2015-09 ,pp. : 443-449

John Wiley & Sons Inc

Access to resources Recommend Favorite

Darifenacin: a selective M₃ muscarinic receptor antagonist for the treatment of overactive bladder

By Smith Phillip P   Lai H Henry   Appell Rodney A  

Therapy, Vol. 3, Iss. 6, 2006-11 ,pp. : 723-732

Future Medicine

Access to resources Recommend Favorite

Impact of overactive bladder on women in the United States: results of a national survey

By Dmochowski Roger R.   Newman Diane K.  

Current Medical Research and Opinion, Vol. 23, Iss. 1, 2007-01 ,pp. : 65-76

Informa Healthcare

Access to resources Recommend Favorite